Delivery Order SPE2DB22D1106-SPE2DB24FDYP5
- Not listed
- This federal contract award is for the delivery of pharmaceutical products, specifically the medication Rexulti 1 mg tablet, to the Defense Logistics Agency (DLA). The contract, valued at $4,866.53, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a Firm Fixed Price Delivery Order that runs until February 22, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- The U.S. Defense Logistics Agency (DLA) awarded a $3,854.64 firm-fixed-price delivery order to Amerisourcebergen Drug Corp's Corporate Office division, a major pharmaceutical supplier to the federal government. This order is for the drug Rexulti (0.25 mg tablet, 30s) and has a completion date of May 21, 2024. Amerisourcebergen holds a single-award Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 2025. This IDC serves as the...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $18,788.81, is for the delivery of the antipsychotic medication Rexulti 1 mg tablets. This is a firm fixed price delivery order contract with a completion date of September 26, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Rexulti 1 mg tablets. The contract, valued at $4,827.31, is a firm fixed-price delivery order with an ultimate completion date of November 2, 2021. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., a for-profit organization registered in the System for Award Management...
- This federal contract award to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation, is a delivery order valued at $11,081.84 for the supply of the pharmaceutical product Rexulti 2 mg tablets. The award was made by the Defense Logistics Agency (DLA), a defense agency of the U.S. Department of Defense, and has a period of performance through March 27, 2024. This delivery order is placed under a larger indefinite delivery...
- This federal contract award is for the delivery of Rexulti 1 mg tablets to the Defense Logistics Agency (DLA) Troop Support Medical. The contract has a ceiling value of $2,323.36 and a completion date of November 7, 2023. The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. This contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, from the Defense Logistics Agency (DLA), a defense agency. The contract is a delivery order with a firm fixed price valued at $10,748.27 and a completion date of June 6, 2025. The contract is for the supply of Rexulti 2 mg tablets, a prescription medication. Amerisourcebergen Drug Corp is the prime contractor and there is no set-aside designation, indicating open...
- This federal contract award from the Defense Logistics Agency (DLA) was issued to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The $2,982.92 firm fixed-price delivery order is for the supply of Rexulti 2 mg tablets. The contract has an ultimate completion date of April 19, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as...
- This federal contract award, valued at $23,807.98, was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of Rexulti 1 mg tablets, a pharmaceutical product, with a performance period through May 3, 2024. The award is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The $2,654.22 firm fixed price delivery order is for the supply of REXULTI 2 MG TABLET 30S, with a period of performance through June 25, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a wide...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB24FDYP5Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The $18,082.03 firm fixed-price delivery order is for the supply of the medication Rexulti 2 mg tablets, with a delivery date of February 5, 2024. This contract is not designated as a set-aside. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, as well as a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation through May 2024. These IDCs enable Amerisourcebergen to efficiently supply a wide range of pharmaceutical products and medical supplies to support federal healthcare programs, including those serving the military, veterans, and other government beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.1k | 2/2/24 |